Indivior Pharmaceuticals Inc

Indivior Pharmaceuticals Inc(INDV)資訊與事件

$35.250

+0.486 (+1.38%)收盤時

INDV 資訊

INDV 事件

10/29 07:30

Indivior Reports Q3 Revenue of $356M

Reports Q3 revenue $356M, consensus $329.35M. "In the third quarter, we delivered record SUBLOCADE net revenue and record adjusted EBITDA, reflecting the strength of our business and the disciplined execution of the Indivior Action Agenda," said Joe Ciaffoni, Chief Executive Officer. "Upon the imminent closing of our merger with Supernus, we will have successfully completed all three phases of the Indivior Action Agenda. I want to thank the Indivior team for their commitment and hard work that generated these results and made the transaction with Supernus possible. I am confident in Supernus' future and its ability to build on this strong foundation for people living with central nervous system diseases and to create long-term value for shareholders."

10/29 07:30

Indivior Sees FY26 Adjusted EBITDA of $700M-$740M

Backs FY26 adjusted EBITDA view $700M-$740M. "We achieved record financial performance in the third quarter, including SUBLOCADE net revenue growth of 22% year-over-year and adjusted EBITDA margin of 59%, up 2,100 basis points year-over-year," said Ryan Preblick, Chief Financial Officer. "Our strong results and the execution of our Indivior Action Agenda puts us on track to achieve our previously communicated 2026 financial guidance, excluding the impact of our pending acquisition. Strong cash generation brought cash and investments to $332 million at quarter end, adding to the financial strength we will bring to our merger with Supernus."

10/28 17:34

Huron Consulting Group to Replace Supernus Pharmaceuticals in S&P SmallCap 600

Huron Consulting Group (HURN) will replace Supernus Pharmaceuticals (SUPN) in the S&P SmallCap 600 before the opening of trading on Tuesday, November 3, instead of Monday, November 2. S&P SmallCap 600 constituent Indivior Pharmaceuticals (INDV) is acquiring Supernus Pharmaceuticals in a transaction expected to close soon, subject to final closing conditions. Post merger, Indivior Pharmaceuticals will assume the name Supernus and will trade under the symbol SUPN. It will remain in the S&P SmallCap 600.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易